<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29299" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Spider Veins</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sandean</surname>
            <given-names>Darren P.</given-names>
          </name>
          <aff>University Hospitals of Leicester</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winters</surname>
            <given-names>Ryan</given-names>
          </name>
          <aff>Ochsner Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Darren Sandean declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Winters declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29299.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Spider veins, also known as telangiectasias or thread veins, are prominent clusters of small, damaged blood vessels visible in the skin.&#x000a0;They appear as&#x000a0;thin red, blue, or purple lines. They are most commonly found on the legs but can also occur elsewhere, particularly on the face. Telangiectasias comes from the Greek words <italic toggle="yes">telos</italic> (end), <italic toggle="yes">angeion</italic> (vessel), and <italic toggle="yes">ektasis</italic> (dilatation).&#x000a0;Spider veins arise from abnormalities in the horizontal vascular plexus of capillary loops in the skin and can have either arterial or venous origins.</p>
        <p>Telangiectasias are also known as thread veins, venus flares, sunburst veins, stellate veins, and hyphen webs. Spider veins rarely cause health issues but may occasionally become painful. However, they are often a cosmetic concern, and treatments primarily focus on improving appearance.&#x000a0;Most patients seek treatment options such as sclerotherapy, intense pulsed light therapy, thermocoagulation, or microphlebectomy. Diagnosis is typically based on clinical examination, with imaging used if venous insufficiency is suspected.&#x000a0;This activity covers the epidemiology, genetics, clinical presentation, and management of spider veins, equipping healthcare professionals with the knowledge and tools to enhance patient care and refer appropriately when patients present with this prevalent condition.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify spider veins and their common presentations, including their appearance, location, and associated symptoms, to ensure accurate diagnosis.</p></list-item><list-item><p>Implement evidence-based treatment options for spider veins, including sclerotherapy, laser therapy, and microphlebectomy, based on individual patient needs,</p></list-item><list-item><p>Select appropriate diagnostic tools and imaging techniques to evaluate the severity of spider veins and associated venous insufficiency.</p></list-item><list-item><p>Collaborate with interprofessional healthcare providers to ensure a comprehensive, multidisciplinary approach to managing spider veins and addressing underlying conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29299&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29299">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29299.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Spider veins, also known as telangiectasias, are prominent clusters of small,&#x000a0;damaged, and superficial blood vessels visible in the skin.&#x000a0;They appear as&#x000a0;thin red, blue, or purple lines. Most commonly found on the legs, spider veins may occur elsewhere, particularly on the face (see&#x000a0;<bold>Image.</bold> Spider Telangiectasis).</p>
        <p>Telangiectasias were first described by von Graf in 1807. "Telangiectasias" is derived from the Greek words&#x000a0;<italic toggle="yes">telos</italic>&#x000a0;(end),&#x000a0;<italic toggle="yes">angeion</italic>&#x000a0;(vessel), and&#x000a0;<italic toggle="yes">ektasis</italic>&#x000a0;(dilatation).<xref ref-type="bibr" rid="article-29299.r1">[1]</xref>&#x000a0;Telangiectasias are also known as thread veins, venus flares, sunburst veins, stellate veins, and hyphen webs.<xref ref-type="bibr" rid="article-29299.r2">[2]</xref>&#x000a0;</p>
        <p>Spider veins rarely cause health issues but may occasionally become painful. However, telangiectasias are often a cosmetic concern, and treatments primarily focus on improving appearance.&#x000a0;</p>
      </sec>
      <sec id="article-29299.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Spider veins result from abnormalities in the horizontal vascular plexus of capillary loops in the skin and can have either arterial or venous origins.<xref ref-type="bibr" rid="article-29299.r3">[3]</xref>&#x000a0;Venous&#x000a0;spider veins are raised, appear blue or purple, and typically measure 1 to 3 mm in diameter. In contrast, arterial spider veins (originating from the arterial capillary loops) are flat, appear pink or red, and range from 0.1 to 1 mm in diameter.<xref ref-type="bibr" rid="article-29299.r4">[4]</xref>&#x000a0;In&#x000a0;the legs, these veins are usually located 180&#x000a0;&#x003bc;m to 1 mm deep within the skin, consisting of a feeder vessel&#x000a0;and ectatic venous sprouts found in the reticular dermis.<xref ref-type="bibr" rid="article-29299.r5">[5]</xref>&#x000a0;</p>
        <p>The exact pathogenesis of spider veins is still unclear. Some theories suggest they may develop from varicose veins and are secondary to a similar mechanism of valvular incompetence seen in chronic venous disease or&#x000a0;chronic venous insufficiency. However, a study found that only 22.9% of patients with spider veins showed evidence of venous incompetence.<xref ref-type="bibr" rid="article-29299.r6">[6]</xref>&#x000a0;</p>
        <p>Goldman proposed that telangiectasias result from local anoxia, leading to endothelial inflammation and vascular neogenesis.<xref ref-type="bibr" rid="article-29299.r7">[7]</xref>&#x000a0;The pathophysiology may involve multiple factors, with spider veins representing the milder side of the spectrum of chronic venous insufficiency and varicose veins at the more severe end. Incompetent valves in the deep venous network allow retrograde blood flow, causing blood to pool in the small superficial vessels. The resulting inflammation and vascular neogenesis from local anoxia cause these vessels to bulge and branch out, giving them a spider-like appearance.</p>
      </sec>
      <sec id="article-29299.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Numerous studies on the epidemiology of spider veins concluded that most adults will eventually develop some form of spider veins in their lifetime. The typical age of presentation is between the ages of 30 and 50.<xref ref-type="bibr" rid="article-29299.r2">[2]</xref>&#x000a0;In a study involving 1566 randomly selected adults in Scotland, Ruckley et al reported that 88% of women and 79% of men had spider veins in their right leg.<xref ref-type="bibr" rid="article-29299.r2">[2]</xref>&#x000a0;Of those affected, 98% experienced only very mild symptoms.</p>
        <p>Chiesa et al studied 4288 patients and found that women were 4 times more likely than men to develop spider veins, with the risk increasing with the number of pregnancies.<xref ref-type="bibr" rid="article-29299.r8">[8]</xref>&#x000a0;They also reported that while men were less likely to be affected, their disease manifestations were more severe, and they were more likely to experience advanced chronic venous insufficiency. Additionally, the risk of developing spider veins increases with obesity and in occupations involving prolonged sitting or standing.<xref ref-type="bibr" rid="article-29299.r9">[9]</xref><xref ref-type="bibr" rid="article-29299.r10">[10]</xref>&#x000a0;</p>
        <p>Some evidence suggests that smoking is associated with spider veins, and other studies have found that local trauma or a history of venous thromboembolism increases the risk of developing spider veins in the affected limb.<xref ref-type="bibr" rid="article-29299.r11">[11]</xref><xref ref-type="bibr" rid="article-29299.r12">[12]</xref>&#x000a0;Additional risk factors include genetics and ethnicity, with 90% of individuals with spider veins having a positive family history and non-Hispanic White people being at higher risk.<xref ref-type="bibr" rid="article-29299.r13">[13]</xref><xref ref-type="bibr" rid="article-29299.r14">[14]</xref>&#x000a0;Other factors predisposing patients to spider veins are the use of topical steroids or female hormones and low-fiber diets.<xref ref-type="bibr" rid="article-29299.r15">[15]</xref><xref ref-type="bibr" rid="article-29299.r16">[16]</xref></p>
      </sec>
      <sec id="article-29299.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Spider veins are primarily an aesthetic issue. A survey reported that telangiectasias of the lower limbs are considered the most concerning cosmetic problem for American women.<xref ref-type="bibr" rid="article-29299.r17">[17]</xref> While most patients are asymptomatic, a minority may experience symptoms such as burning, itching, pain, cramps, or leg fatigue.<xref ref-type="bibr" rid="article-29299.r7">[7]</xref>&#x000a0;</p>
        <p>Patients may have one or more risk factors and a history of chronic venous insufficiency, including varicose veins or venous eczema. Physical examination may reveal spider veins that may be raised or flat and may appear as thin blue, red, or purple vessels, depending on whether they are arterial or venous in origin. Telangiectasia can form anywhere on the body and at any age, though most patients develop spider veins on their legs and face.</p>
      </sec>
      <sec id="article-29299.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of spider veins is primarily clinical. There are no laboratory tests useful for diagnosing spider veins. However, imaging studies can help map the venous system if chronic venous insufficiency is suspected. These studies include duplex ultrasound, contrast venography, and magnetic resonance venography.</p>
        <p>Spider veins are categorized in the Clinical, Etiological, Anatomical, and Pathological (CEAP) classification system for chronic venous insufficiency, which includes the following 7 categories: 0 through 6.<xref ref-type="bibr" rid="article-29299.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>C0: Absence of venous disease</p>
          </list-item>
          <list-item>
            <p>C1: Telangiectasias and larger reticular veins</p>
          </list-item>
          <list-item>
            <p>C2: Varicose veins (3 mm or greater in diameter)</p>
          </list-item>
          <list-item>
            <p>C3: Edema</p>
          </list-item>
          <list-item>
            <p>C4: Changes in skin and subcutaneous tissue, including pigmentation&#x000a0;(C4a), eczema (C4a), lipodermatosclerosis (C4b), or atrophie blanche (C4b)</p>
          </list-item>
          <list-item>
            <p>C5: Healed venous ulcer</p>
          </list-item>
          <list-item>
            <p>C6: Active venous ulcer</p>
          </list-item>
        </list>
        <p>Telangiectasia is defined as a confluence of dilated intradermal venules less than 1 mm in caliber.<xref ref-type="bibr" rid="article-29299.r18">[18]</xref>&#x000a0;Redisch&#x000a0;and Pelzer further classified telangiectasias into the following 4 types based on their clinical appearance.<xref ref-type="bibr" rid="article-29299.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Simple linear</p>
          </list-item>
          <list-item>
            <p>Spider: Radiating from a central locus</p>
          </list-item>
          <list-item>
            <p>Arborizing: Arranged like branches on a tree</p>
          </list-item>
          <list-item>
            <p>Papular: Discrete round spots</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29299.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Spider veins are usually harmless and asymptomatic, with most patients pursuing treatment primarily for reduction, removal, or aesthetics. Treatment options include sclerotherapy, intense pulsed light (IPL) therapy, thermocoagulation, and microphlebectomy. The choice of treatment, whether used alone or in combination, depends on individual patient factors.<xref ref-type="bibr" rid="article-29299.r20">[20]</xref></p>
        <p>
<bold>Sclerotherapy</bold>
</p>
        <p>Telangiectasias and reticular veins can be treated by injecting sclerosing agents into the vessels to obliterate them. Sclerotherapy is considered the first-line treatment for spider veins on the legs. The local vasculature is first assessed with ultrasonography to examine the deep, superficial, feeder, and perforating veins for obstruction and venous reflux or incompetence. Abnormal flow pathways are identified, and the target vessels for treatment are marked accordingly. The sclerosing agent, either in liquid or foam form, is injected with a fine 30-gauge needle under ultrasound guidance. This agent works by causing endothelial damage, leading to fibrosis of the vessel and halting blood flow. Various sclerosing substances are used in sclerotherapy, categorized as detergents, osmotic agents, or chemical irritants.</p>
        <p>Detergents such as polidocanol and sodium tetradecyl cause endothelial injury by disrupting surface tension around endothelial cells. Chemical irritants, such as chromated glycerin, achieve their effect through cauterization. Osmotic agents, including hypertonic saline and dextrose, dehydrate endothelial cells. For larger reticular veins, foam sclerotherapy may be more appropriate.<xref ref-type="bibr" rid="article-29299.r21">[21]</xref>&#x000a0;Foam sclerotherapy involves mixing a fluid such as polidocanol or sodium tetradecyl sulfate with gas to create foam. Over time, the treated vessels fade, are resorbed, and disappear. However, the treatment does not prevent the formation of new vessels from forming, and multiple treatments may be required to achieve the desired effect.</p>
        <p>Sclerotherapy is a widely used treatment for spider veins, with some studies showing a 50% to 70% improvement in patients.<xref ref-type="bibr" rid="article-29299.r22">[22]</xref>&#x000a0;Common adverse effects of sclerotherapy include transient hyperpigmentation, ulceration, sloughing, allergy, thrombophlebitis, swelling, and pain. More severe but rare adverse effects include thromboembolic events, anaphylaxis, and transient visual disturbances.&#x000a0;</p>
        <p>
<bold>Laser Treatment and Intense Pulsed Light Treatment</bold>
</p>
        <p>Laser and IPL therapy are noninvasive methods for treating spider veins with a diameter smaller than a 30-gauge needle. These treatments are especially useful for patients with spider veins on the face, which may not be suitable for sclerotherapy. This treatment is also recommended for patients allergic to sclerosing agents or those who are needle-phobic.</p>
        <p>A basic appreciation of laser theory is essential to understand the suitability, limitations, and adverse effects of this treatment. Laser therapy is administered through a hand-held device, which works by heating the target as it absorbs energy from the laser's photons. The target absorbs this energy only if the laser's wavelength matches the chromophore of the target, meaning the target must be of a specific color. By adjusting the laser wavelength, different chromophores, and thus different structures, can be selectively targeted while minimizing harm to surrounding tissues.</p>
        <p>In spider vein therapy, light energy is absorbed by hemoglobin in the damaged vessels. This absorption heats the vessels, causing them to occlude through thrombus formation via photocoagulation. The concept of selective photolysis, developed by Anderson and Parrish in 1983, underpins modern laser therapy in medicine today.<xref ref-type="bibr" rid="article-29299.r23">[23]</xref></p>
        <p>
<bold>Types of Lasers for Spider Vein Treatment</bold>
</p>
        <p>Various lasers are available for treating spider veins, each with its advantages, drawbacks, and specific applications.</p>
        <p><bold>Argon laser:&#x000a0;</bold>Argon lasers were among the first employed for vascular treatments. These lasers emit a blue-green wavelength in the range of 488 to 514 nm, which is well absorbed by hemoglobin and penetrates about 1 mm into the skin. Studies have reported success rates of up to 90% when used with sclerotherapy.<xref ref-type="bibr" rid="article-29299.r24">[24]</xref><xref ref-type="bibr" rid="article-29299.r25">[25]</xref>&#x000a0;However, argon lasers carry a higher risk of scarring and pigmentation, likely due to their nonspecific thermal injury.<xref ref-type="bibr" rid="article-29299.r25">[25]</xref></p>
        <p><bold>Pulsed dye laser:&#x000a0;</bold>Pulsed dye lasers, with long wavelengths of 595 nm and extended pulse durations of 40 ms, are effective in treating spider veins.<xref ref-type="bibr" rid="article-29299.r26">[26]</xref>&#x000a0;Modern versions of pulsed dye lasers feature integrated cooling devices and use pulses shorter than the relaxation time of small vessels (1 ms). These characteristics help reduce the risk of unintended thermal damage to surrounding tissues, reducing scarring and pigmentation. Pulsed dye lasers are effective for clearing small-caliber vessels, but their performance with larger-caliber vessels has not been as promising or successful.<xref ref-type="bibr" rid="article-29299.r27">[27]</xref><xref ref-type="bibr" rid="article-29299.r28">[28]</xref></p>
        <p><bold>Nd:YAG laser:</bold>&#x000a0;With a&#x000a0;longer wavelength of 1064 nm, Nd:YAG lasers&#x000a0;are effective for treating larger caliber veins. They are highly effective in spider vein therapy but may not be the most favored among patients due to the discomfort they can cause. Besides increased pain, Nd:YAG lasers can also cause hyperpigmentation.</p>
        <p><bold>Potassium-titanyl-phosphate laser:&#x000a0;</bold>Potassium-titanyl-phosphate (KTP) lasers double the frequency of Nd:YAG lasers by passing the light through a KTP crystal. The resultant light is in the wavelength range of 532 to 1064 nm. This higher frequency makes KTP lasers suitable for darker skin patients and smaller vessels. They are commonly used for facial spider veins due to their limited penetration but are less effective for treating spider veins on the legs.</p>
        <p><bold>Pulsed diode laser:</bold> Pulsed diode lasers emit photons within the range of 800 to 900 nm. These lasers have an excellent profile, largely due to their integrated cooling devices and minimal inflammatory effects. Numerous studies have reported high clearance rates for leg spider veins with pulsed diode lasers.<xref ref-type="bibr" rid="article-29299.r29">[29]</xref><xref ref-type="bibr" rid="article-29299.r30">[30]</xref></p>
        <p>Overall, laser treatments are safe and effective methods of treating spider veins. They are noninvasive and are often preferred by patients with facial spider veins or those who are averse to needles. Adverse effects can include blistering, crusting, swelling, and spotting. Contraindications to laser therapy include pregnancy, blood-thinning medication, photosensitive or hypertrophic or keloidal scarring disorders, untreated varicose veins, and, in some cases, recent tanning or darker skin type. Patients are instructed to avoid aspirin, nonsteroidal anti-inflammatory drugs, and blood thinners before the procedure and for 48 hours afterward.&#x000a0;</p>
        <p>
<bold>Microphlebectomy</bold>
</p>
        <p>Microphlebectomy involves the extraction of veins through minute skin incisions (1-3 mm) or needle punctures using specialized hooks. This technique minimizes the risk of complications associated with other treatments, including scarring, skin necrosis, and residual hyperpigmentation.<xref ref-type="bibr" rid="article-29299.r31">[31]</xref></p>
        <p>
<bold>Thermocoagulation</bold>
</p>
        <p>Similar to other treatment methods, thermocoagulation works by causing endothelial damage to the target vessel. This technique uses a high-frequency (radio frequency) pulse delivered through a fine needle inserted into the target vessel. When the temperature reaches 70 &#x000b0;C, the vessel is occluded through thermocoagulation. Over time, the vessel is resorbed and fades. Recent studies indicate that radiofrequency coagulation is more effective than sclerotherapy in eliminating small veins less than 0.3 mm in diameter.<xref ref-type="bibr" rid="article-29299.r32">[32]</xref><xref ref-type="bibr" rid="article-29299.r33">[33]</xref></p>
      </sec>
      <sec id="article-29299.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Spider veins can be associated with chronic venous insufficiency and may occur concomitantly with varicose veins, venous eczema, stasis dermatitis, and leg ulcers. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/31060">Venous Insufficiency</ext-link>," for more information.<xref ref-type="bibr" rid="article-29299.r34">[34]</xref>&#x000a0;These conditions are more severe and require medical attention before addressing spider veins, which are primarily a cosmetic concern. As spider veins can be an early indicator of chronic venous insufficiency, clinicians should be vigilant for undiagnosed venous disease in patients presenting with spider veins.</p>
        <p>Spider angiomas can sometimes resemble spider veins. Although generally harmless, spider angiomas may indicate more severe systemic conditions, such as rheumatoid arthritis, thyroid disease, or liver disease. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/36261">Spider Angioma</ext-link>," for more information.&#x000a0;Unlike spider veins, spider angiomas feature a central red spot with radiating, web-like extensions.</p>
      </sec>
      <sec id="article-29299.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Untreated spider veins are primarily a cosmetic issue and do not cause significant medical problems or functional impairment. However, in severe cases affecting the legs or face, they can impact a patient&#x02019;s self-esteem and lead to psychological issues, especially in young females who are more body-conscious.</p>
      </sec>
      <sec id="article-29299.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from untreated spider veins are rare and generally do not pose significant health risks. However, in severe cases associated with varicose veins, there is a higher risk of developing sores, skin ulcers, and thrombophlebitis. As with any procedure, therapeutic treatments for spider veins carry some risk of complications, but these risks are very low.</p>
      </sec>
      <sec id="article-29299.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Naturally, little can be done to address non-modifiable risk factors such as age, sex, ethnicity, and gravidity. However, other factors can be managed through maintaining a healthy body mass index (BMI), quitting smoking, staying active, and avoiding tight clothing near the spider veins. Some evidence suggests that compression stockings may help prevent the formation of new spider veins after treatment.<xref ref-type="bibr" rid="article-29299.r35">[35]</xref></p>
      </sec>
      <sec id="article-29299.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As a purely cosmetic issue, spider veins often involve an interprofessional team in aesthetic medicine, including dermatologists, aestheticians, and plastic surgeons. Patients may initially see their general practitioner, who might refer them subsequently to a dermatologist or plastic surgeon.</p>
        <p>In many healthcare systems, spider vein treatments are categorized as aesthetic procedures, so government or insurance funding may be limited. A significant commercial market exists, and savvy practitioners should guide patients toward reputable aesthetic medicine providers.&#x000a0;The&#x000a0;treating practitioner should&#x000a0;have an open discussion with the patient about the goals, risks, benefits, and out-of-pocket costs associated with any treatment plan, allowing the patient to make an informed decision. The interprofessional team members need to know when to refer to specialists when the condition warrants.&#x000a0;</p>
      </sec>
      <sec id="article-29299.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29299&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29299">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/spider-veins/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29299">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29299/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29299">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29299.s14">
        <fig id="article-29299.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Spider Telangiectasis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="spider__telangiectasis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29299.s15">
        <title>References</title>
        <ref id="article-29299.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merlen</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>[Red telangiectasis, blue telangiectasis].</article-title>
            <source>Phlebologie</source>
            <year>1970</year>
            <season>Apr-Jun</season>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-74</page-range>
            <pub-id pub-id-type="pmid">5448639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruckley</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fowkes</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Telangiectasia in the Edinburgh Vein Study: epidemiology and association with trunk varices and symptoms.</article-title>
            <source>Eur J Vasc Endovasc Surg</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>719</fpage>
            <page-range>719-24</page-range>
            <pub-id pub-id-type="pmid">18848475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braverman</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>The cutaneous microcirculation.</article-title>
            <source>J Investig Dermatol Symp Proc</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">11147672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy of telangiectasias or spider veins in the lower limb: A review.</article-title>
            <source>J Vasc Nurs</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-2</page-range>
            <pub-id pub-id-type="pmid">27210454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;hler-Sommeregger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karnel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schuller-Petrovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santler</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Do telangiectases communicate with the deep venous system?</article-title>
            <source>J Dermatol Surg Oncol</source>
            <year>1992</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>403</fpage>
            <page-range>403-6</page-range>
            <pub-id pub-id-type="pmid">1607463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thibault</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Recurrent varicose veins. Part 1: Evaluation utilizing duplex venous imaging.</article-title>
            <source>J Dermatol Surg Oncol</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>618</fpage>
            <page-range>618-24</page-range>
            <pub-id pub-id-type="pmid">1624636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy for lower limb telangiectasias.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Dec</month>
            <day>07</day>
            <volume>2011</volume>
            <issue>12</issue>
            <fpage>CD008826</fpage>
            <pub-id pub-id-type="pmid">22161437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiesa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marone</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Limoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Volont&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petrini</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Demographic factors and their relationship with the presence of CVI signs in Italy: the 24-cities cohort study.</article-title>
            <source>Eur J Vasc Endovasc Surg</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>674</fpage>
            <page-range>674-80</page-range>
            <pub-id pub-id-type="pmid">16055355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jawien</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The influence of environmental factors in chronic venous insufficiency.</article-title>
            <source>Angiology</source>
            <year>2003</year>
            <season>Jul-Aug</season>
            <volume>54 Suppl 1</volume>
            <fpage>S19</fpage>
            <page-range>S19-31</page-range>
            <pub-id pub-id-type="pmid">12934754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacroix</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aboyans</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Preux</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Houl&#x000e8;s</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Laskar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of venous insufficiency in an occupational population.</article-title>
            <source>Int Angiol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-6</page-range>
            <pub-id pub-id-type="pmid">12865883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gourgou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dedieu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sancho-Garnier</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Lower limb venous insufficiency and tobacco smoking: a case-control study.</article-title>
            <source>Am J Epidemiol</source>
            <year>2002</year>
            <month>Jun</month>
            <day>01</day>
            <volume>155</volume>
            <issue>11</issue>
            <fpage>1007</fpage>
            <page-range>1007-15</page-range>
            <pub-id pub-id-type="pmid">12034579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Solymoss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamping</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Abenhaim</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life.</article-title>
            <source>J Gen Intern Med</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>425</fpage>
            <page-range>425-9</page-range>
            <pub-id pub-id-type="pmid">10886478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of 500 consecutive patients presenting for laser removal of lower extremity spider veins.</article-title>
            <source>Dermatol Surg</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-3</page-range>
            <pub-id pub-id-type="pmid">11231238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Criqui</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jamosmos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fronek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denenberg</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Bergan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Golomb</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Chronic venous disease in an ethnically diverse population: the San Diego Population Study.</article-title>
            <source>Am J Epidemiol</source>
            <year>2003</year>
            <month>Sep</month>
            <day>01</day>
            <volume>158</volume>
            <issue>5</issue>
            <fpage>448</fpage>
            <page-range>448-56</page-range>
            <pub-id pub-id-type="pmid">12936900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol.</article-title>
            <source>Dermatol Surg</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-5</page-range>
            <pub-id pub-id-type="pmid">11991271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadick</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Predisposing factors of varicose and telangiectatic leg veins.</article-title>
            <source>J Dermatol Surg Oncol</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>883</fpage>
            <page-range>883-6</page-range>
            <pub-id pub-id-type="pmid">1430543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Maeseneer</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kakkos</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Aherne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baekgaard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blomgren</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giannoukas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gohel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Graaf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hamel-Desnos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jawien</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaworucka-Kaczorowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lattimer</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Mosti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Noppeney</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stansby</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esvs Guidelines Committee</surname>
              </name>
              <name>
                <surname>Kolh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bastos Goncalves</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chakf&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Coscas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Borst</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Hinchliffe</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Koncar</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Lindholt</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tulamo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Twine</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Vermassen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wanhainen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Document Reviewers</surname>
              </name>
              <name>
                <surname>Bj&#x000f6;rck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Labropoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lurie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mansilha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nyamekye</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Ramirez Ortega</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulloa</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Urbanek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Rij</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vuylsteke</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs.</article-title>
            <source>Eur J Vasc Endovasc Surg</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>184</fpage>
            <page-range>184-267</page-range>
            <pub-id pub-id-type="pmid">35027279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ekl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bergan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Carpentier</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gloviczki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kistner</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Moneta</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Padberg</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruckley</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>TW</given-names>
              </name>
              <collab>American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification</collab>
            </person-group>
            <article-title>Revision of the CEAP classification for chronic venous disorders: consensus statement.</article-title>
            <source>J Vasc Surg</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1248</fpage>
            <page-range>1248-52</page-range>
            <pub-id pub-id-type="pmid">15622385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>REDISCH</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>PELZER</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Localized vascular dilatations of the human skin, capillary microscopy and related studies.</article-title>
            <source>Am Heart J</source>
            <year>1949</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-13</page-range>
            <pub-id pub-id-type="pmid">18104384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakano</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Cacione</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Baptista-Silva</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Flumignan</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Treatment for telangiectasias and reticular veins.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Oct</month>
            <day>12</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD012723</fpage>
            <pub-id pub-id-type="pmid">34637138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porsalman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khatony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sobhiyeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of foam sclerotherapy versus radiofrequency ablation in the treatment of primary varicose veins due to incompetent great saphenous vein: Randomized clinical trial.</article-title>
            <source>J Vasc Nurs</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>226</fpage>
            <page-range>226-231</page-range>
            <pub-id pub-id-type="pmid">31847976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parlar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blazek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cazzaniga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kloetgen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Borradori</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buettiker</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>549</fpage>
            <page-range>549-54</page-range>
            <pub-id pub-id-type="pmid">25069999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation.</article-title>
            <source>Science</source>
            <year>1983</year>
            <month>Apr</month>
            <day>29</day>
            <volume>220</volume>
            <issue>4596</issue>
            <fpage>524</fpage>
            <page-range>524-7</page-range>
            <pub-id pub-id-type="pmid">6836297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apfelberg</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Maser</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lash</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Flores</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Use of the argon and carbon dioxide lasers for treatment of superficial venous varicosities of the lower extremity.</article-title>
            <source>Lasers Surg Med</source>
            <year>1984</year>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-31</page-range>
            <pub-id pub-id-type="pmid">6438415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous laser therapy.</article-title>
            <source>West J Med</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>143</volume>
            <issue>6</issue>
            <fpage>758</fpage>
            <page-range>758-63</page-range>
            <pub-id pub-id-type="pmid">4090490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>The new-generation, high-energy, 595 nm, long pulse-duration, pulsed-dye laser effectively removes spider veins of the lower extremity.</article-title>
            <source>Lasers Surg Med</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>218</fpage>
            <page-range>218-24</page-range>
            <pub-id pub-id-type="pmid">17096414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dover</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>New approaches to the treatment of vascular lesions.</article-title>
            <source>Lasers Surg Med</source>
            <year>2000</year>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-63</page-range>
            <pub-id pub-id-type="pmid">10685088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lowery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Geronemus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lask</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of spider veins with the 595 nm pulsed-dye laser.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>5 Pt 1</issue>
            <fpage>746</fpage>
            <page-range>746-50</page-range>
            <pub-id pub-id-type="pmid">9810891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lanigan</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Laser therapy of telangiectatic leg veins: clinical evaluation of the 810 nm diode laser.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>419</fpage>
            <page-range>419-22</page-range>
            <pub-id pub-id-type="pmid">11012600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eremia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Umar</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>A side-by-side comparative study of 1064 nm Nd:YAG, 810 nm diode and 755 nm alexandrite lasers for treatment of 0.3-3 mm leg veins.</article-title>
            <source>Dermatol Surg</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>224</fpage>
            <page-range>224-30</page-range>
            <pub-id pub-id-type="pmid">11896773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramelet</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Phlebectomy. Technique, indications and complications.</article-title>
            <source>Int Angiol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>2 Suppl 1</issue>
            <fpage>46</fpage>
            <page-range>46-51</page-range>
            <pub-id pub-id-type="pmid">12515980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korolova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Korolova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Teplyi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sydorenko</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>MINI-INVASIVE TREATMENT METHODS OF SPIDER VEINS: SCLEROTHERAPY AND RADIOFREQUENCY THERMOCOAGULATION.</article-title>
            <source>Wiad Lek</source>
            <year>2023</year>
            <volume>76</volume>
            <issue>9</issue>
            <fpage>1992</fpage>
            <page-range>1992-1999</page-range>
            <pub-id pub-id-type="pmid">37898935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diken</surname>
                <given-names>A&#x00130;</given-names>
              </name>
              <name>
                <surname>Alemdaro&#x0011f;lu</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>&#x000d6;zyal&#x000e7;&#x00131;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>&#x00130;</given-names>
              </name>
              <name>
                <surname>T&#x000fc;nel</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yal&#x000e7;&#x00131;nkaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ecevit</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant radiofrequency thermocoagulation improves the outcome of liquid sclerotherapy in the treatment of spider veins of the leg: A pilot study.</article-title>
            <source>Phlebology</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>620</fpage>
            <page-range>620-626</page-range>
            <pub-id pub-id-type="pmid">33813962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partsch</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Varicose veins and chronic venous insufficiency.</article-title>
            <source>Vasa</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-301</page-range>
            <pub-id pub-id-type="pmid">19998250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29299.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kern</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramelet</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>W&#x000fc;tschert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hayoz</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study.</article-title>
            <source>J Vasc Surg</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1212</fpage>
            <page-range>1212-6</page-range>
            <pub-id pub-id-type="pmid">17467226</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
